ERAS

Erasca, Inc.

• Simply Wall St·1d ago

  Assessing Erasca (ERAS) Valuation After ERAS-0015 Trial Progress And Supportive FDA And Analyst Updates

• NASDAQ·6d ago

  ERAS Crosses Above Average Analyst Target

• Reuters·6d ago

  Erasca Chief Legal Officer Ebun Garner disposes of 80,000 shares for $1.3 million

• TipRanks·6d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Benzinga·03/31 13:57

  Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

• The Motley Fool·03/26 22:04

  Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't

• TipRanks·03/26 12:21

  Analysts Conflicted on These Healthcare Names: Erasca (ERAS) and Mereo Biopharma Group Plc (MREO)

• TipRanks·03/25 16:30

  Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007

• TipRanks·03/24 10:18

  Bank of America Securities Reaffirms Their Sell Rating on Erasca (ERAS)

• Seeking Alpha·03/23 18:47

  Top performing mid-cap stocks YTD as volatility hits markets

• Simply Wall St·03/22 02:05

  A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally

• Simply Wall St·03/20 16:14

  How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors

• Dow Jones·03/18 15:55

  Erasca Price Target Raised to $25.00/Share From $24.00 by JP Morgan

• Dow Jones·03/18 15:55

  Erasca Is Maintained at Overweight by JP Morgan

• Benzinga·03/18 15:46

  JP Morgan Maintains Overweight on Erasca, Raises Price Target to $25